ReviewFrontiers in immunology2026
Polysaccharide-mediated modulation of gut microbiota and lysine lactylation: implications for tumor microenvironment remodeling and cancer immunotherapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the revolutionary clinical benefits of immune checkpoint inhibitors (ICIs), their therapeutic efficacy is largely hampered by the immunosuppressive tumor microenvironment (TME) as well as primary and acquired drug resistance. Natural polysaccharides serve as promising immunomodulators to boost anti-tumor immunity, yet their systematic regulatory network remains poorly characterized. Accumulating evidence demonstrates that gut microbiota and its fermentative metabolites, including short-chain fatty acids and lactate, govern systemic immune surveillance and determine patient responsiveness to ICIs. Meanwhile, lysine lactylation (Kla), a lactate-dependent epigenetic modification, drives glycolytic reprogramming and facilitates tumor immune evasion. This mechanistic review systematically synthesizes current literature and proposes a hypothetical triple regulatory axis: natural polysaccharides act as prebiotics to reshape gut microbial composition and modulate lactate homeostasis, thereby connecting polysaccharide effects, gut microbiota metabolism and lysine lactylation signaling. We comprehensively elaborate how this axis may mediate epigenetic remodeling and immune-cell functional plasticity to reverse TME-derived immunosuppression and confer potential synergistic benefits with anti-PD-1/PD-L1 immunotherapy, benefits so far largely supported by preclinical observations. Notably, although fragmented observational evidence supports this conceptual cascade, direct experimental proof validating the complete causal chain is still lacking. By constructing an integrated metabolic-epigenetic-immune crosstalk framework, this review provides theoretical foundations for developing polysaccharide-based microbiota-targeting adjuvants to overcome ICI resistance. We further summarize major translational bottlenecks and discuss preclinical as well as clinical strategies targeting this cascade to advance tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.